Laurus Labs reports sharply higher Q2 profit as revenue rises 33%

Laurus Labs posts a stronger September quarter

Laurus Labs reported consolidated net profit of ₹436.74 crore for the September quarter, compared with ₹195 crore in the corresponding quarter of the previous financial year. Revenue from operations rose 33% to ₹2,206.37 crore from ₹1,653.47 crore. Other coverage of the results rounded consolidated profit to ₹441 crore or ₹442 crore, while broadly reporting the same year-on-year increase.

The Hyderabad-based pharmaceutical and biotechnology company attributed the performance to its CDMO platform and affordable-medicines portfolio. Founder and Chief Executive Officer Satyanarayana Chava described the quarter as another record period for revenue and profit.

Operating earnings also increased

CNBC-TV18 reported that earnings before interest, tax, depreciation and amortization rose 86% year over year to ₹750 crore, from ₹403.3 crore. It said the EBITDA margin widened to 34% from 24.4%.

Revenue for Q2 FY27 was also 8.9% above the ₹2,026 crore recorded in Q1 FY27, based on the quarterly figures in the reviewed coverage. Net profit was reported as approximately 20.2% higher than the ₹368 crore recorded in the preceding quarter.

A commercial-scale peptide plant is operating

Laurus Labs said it had operationalized its first commercial-scale peptide plant in Visakhapatnam. The company also said a significant capacity expansion was already under way to address what it described as surging demand for peptide therapeutics.

The reviewed reporting does not quantify the plant’s production capacity, expected revenue contribution or the scale of the expansion.

Board approves two acquisitions

Laurus Labs’ board approved the acquisition of 60% of Canada-based Galenvs Sciences Inc. at a pre-money valuation of $3.5 million. The company proposed to invest $3.75 million, comprising a $2.75 million primary infusion and a $1 million secondary purchase from the founder shareholder. Galenvs is described as a contract research and development organization specializing in custom oligonucleotide synthesis and functional magnetic nanoparticle technologies for diagnostic and therapeutic applications.

The board also approved the acquisition of 52% of SI & C Resins Private Limited at a pre-money valuation of ₹30 crore. Laurus plans to invest ₹32.5 crore, making SI&C a subsidiary. The company may invest up to another ₹30 crore in SI&C securities as and when the business requires funding. SI&C manufactures polymer- and silica-based products used in the chemical, pharmaceutical and biotechnology industries.

The acquisitions were presented as planned transactions in the reviewed coverage; completion details were not supplied in the reviewed passages.

Interim dividend approved

The board approved an interim dividend of ₹1 per equity share of ₹2 face value for FY27. The record date is November 6, 2026, and payment is scheduled for on or after November 19, 2026.